Cargando…

Minimally Invasive Versus open AbdominoThoracic Esophagectomy for esophageal carcinoma (MIVATE) — study protocol for a randomized controlled trial DRKS00016773

BACKGROUND: The only curative treatment for most esophageal cancers is radical esophagectomy. Minimally invasive esophagectomy (MIE) aims to reduce postoperative morbidity, but is not yet widely established. Linear stapled anastomosis is a promising technique for MIE because it is quite feasible eve...

Descripción completa

Detalles Bibliográficos
Autores principales: Nickel, Felix, Probst, Pascal, Studier-Fischer, Alexander, Nienhüser, Henrik, Pauly, Jana, Kowalewski, Karl-Friedrich, Weiterer, Sebastian, Knebel, Philipp, Diener, Markus K., Weigand, Markus A., Büchler, Markus W., Schmidt, Thomas, Müller-Stich, Beat P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7798277/
https://www.ncbi.nlm.nih.gov/pubmed/33430937
http://dx.doi.org/10.1186/s13063-020-04966-z
_version_ 1783635029933424640
author Nickel, Felix
Probst, Pascal
Studier-Fischer, Alexander
Nienhüser, Henrik
Pauly, Jana
Kowalewski, Karl-Friedrich
Weiterer, Sebastian
Knebel, Philipp
Diener, Markus K.
Weigand, Markus A.
Büchler, Markus W.
Schmidt, Thomas
Müller-Stich, Beat P.
author_facet Nickel, Felix
Probst, Pascal
Studier-Fischer, Alexander
Nienhüser, Henrik
Pauly, Jana
Kowalewski, Karl-Friedrich
Weiterer, Sebastian
Knebel, Philipp
Diener, Markus K.
Weigand, Markus A.
Büchler, Markus W.
Schmidt, Thomas
Müller-Stich, Beat P.
author_sort Nickel, Felix
collection PubMed
description BACKGROUND: The only curative treatment for most esophageal cancers is radical esophagectomy. Minimally invasive esophagectomy (MIE) aims to reduce postoperative morbidity, but is not yet widely established. Linear stapled anastomosis is a promising technique for MIE because it is quite feasible even without robotic assistance. The aim of the present study is to compare total MIE with linear stapled anastomosis to open esophagectomy (OE) with circular stapled anastomosis with special regard to postoperative morbidity in an expertise-based randomized controlled trial (RCT). METHODS/DESIGN: This superiority RCT compares MIE with linear stapled anastomosis (intervention) to OE with circular stapled anastomosis (control) for Ivor-Lewis esophagectomy. It was initiated in February 2019, and recruitment is expected to last for 3 years. For inclusion, patients must be 18 years of age or more with a resectable primary malignancy in the distal esophagus. Participants with tumor localizations above the azygos vein, metastasis, or infiltration into adjacent tissue will be excluded. In an expertise-based approach, the allocated treatment will only be carried out by the single most experienced surgeon of the surgical center for each respective technique. The sample size was calculated with 20 participants per group for the primary endpoint postoperative morbidity according to comprehensive complication index (CCI) within 30 postoperative days. Secondary endpoints include anastomotic insufficiency, pulmonary complications, other intra- and postoperative outcome parameters such as estimated blood loss, operative time, length of stay, short-term oncologic endpoints, adherence to a standardized fast-track protocol, postoperative pain, and postoperative recovery (QoR-15). Quality of life (SF-36, CAT EORTC QLQ-C30, CAT EORTC QLQ-OES18) and oncological outcomes are evaluated with 60 months follow-up. DISCUSSION: MIVATE is the first RCT to compare OE with circular stapled anastomosis to total MIE with linear stapled anastomosis exclusively for intrathoracic anastomosis. The expertise-based approach limits bias due to heterogeneity of surgical expertise. The use of a dedicated fast-track protocol in both OE and MIE will shed light on the role of the access strategy alone in this setting. The findings of this study will serve to define which approach has the best perioperative outcome for patients requiring esophagectomy. TRIAL REGISTRATION: German Clinical Trials Register DRKS00016773. Registered on 18 February 2019. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-020-04966-z.
format Online
Article
Text
id pubmed-7798277
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-77982772021-01-12 Minimally Invasive Versus open AbdominoThoracic Esophagectomy for esophageal carcinoma (MIVATE) — study protocol for a randomized controlled trial DRKS00016773 Nickel, Felix Probst, Pascal Studier-Fischer, Alexander Nienhüser, Henrik Pauly, Jana Kowalewski, Karl-Friedrich Weiterer, Sebastian Knebel, Philipp Diener, Markus K. Weigand, Markus A. Büchler, Markus W. Schmidt, Thomas Müller-Stich, Beat P. Trials Study Protocol BACKGROUND: The only curative treatment for most esophageal cancers is radical esophagectomy. Minimally invasive esophagectomy (MIE) aims to reduce postoperative morbidity, but is not yet widely established. Linear stapled anastomosis is a promising technique for MIE because it is quite feasible even without robotic assistance. The aim of the present study is to compare total MIE with linear stapled anastomosis to open esophagectomy (OE) with circular stapled anastomosis with special regard to postoperative morbidity in an expertise-based randomized controlled trial (RCT). METHODS/DESIGN: This superiority RCT compares MIE with linear stapled anastomosis (intervention) to OE with circular stapled anastomosis (control) for Ivor-Lewis esophagectomy. It was initiated in February 2019, and recruitment is expected to last for 3 years. For inclusion, patients must be 18 years of age or more with a resectable primary malignancy in the distal esophagus. Participants with tumor localizations above the azygos vein, metastasis, or infiltration into adjacent tissue will be excluded. In an expertise-based approach, the allocated treatment will only be carried out by the single most experienced surgeon of the surgical center for each respective technique. The sample size was calculated with 20 participants per group for the primary endpoint postoperative morbidity according to comprehensive complication index (CCI) within 30 postoperative days. Secondary endpoints include anastomotic insufficiency, pulmonary complications, other intra- and postoperative outcome parameters such as estimated blood loss, operative time, length of stay, short-term oncologic endpoints, adherence to a standardized fast-track protocol, postoperative pain, and postoperative recovery (QoR-15). Quality of life (SF-36, CAT EORTC QLQ-C30, CAT EORTC QLQ-OES18) and oncological outcomes are evaluated with 60 months follow-up. DISCUSSION: MIVATE is the first RCT to compare OE with circular stapled anastomosis to total MIE with linear stapled anastomosis exclusively for intrathoracic anastomosis. The expertise-based approach limits bias due to heterogeneity of surgical expertise. The use of a dedicated fast-track protocol in both OE and MIE will shed light on the role of the access strategy alone in this setting. The findings of this study will serve to define which approach has the best perioperative outcome for patients requiring esophagectomy. TRIAL REGISTRATION: German Clinical Trials Register DRKS00016773. Registered on 18 February 2019. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-020-04966-z. BioMed Central 2021-01-11 /pmc/articles/PMC7798277/ /pubmed/33430937 http://dx.doi.org/10.1186/s13063-020-04966-z Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Study Protocol
Nickel, Felix
Probst, Pascal
Studier-Fischer, Alexander
Nienhüser, Henrik
Pauly, Jana
Kowalewski, Karl-Friedrich
Weiterer, Sebastian
Knebel, Philipp
Diener, Markus K.
Weigand, Markus A.
Büchler, Markus W.
Schmidt, Thomas
Müller-Stich, Beat P.
Minimally Invasive Versus open AbdominoThoracic Esophagectomy for esophageal carcinoma (MIVATE) — study protocol for a randomized controlled trial DRKS00016773
title Minimally Invasive Versus open AbdominoThoracic Esophagectomy for esophageal carcinoma (MIVATE) — study protocol for a randomized controlled trial DRKS00016773
title_full Minimally Invasive Versus open AbdominoThoracic Esophagectomy for esophageal carcinoma (MIVATE) — study protocol for a randomized controlled trial DRKS00016773
title_fullStr Minimally Invasive Versus open AbdominoThoracic Esophagectomy for esophageal carcinoma (MIVATE) — study protocol for a randomized controlled trial DRKS00016773
title_full_unstemmed Minimally Invasive Versus open AbdominoThoracic Esophagectomy for esophageal carcinoma (MIVATE) — study protocol for a randomized controlled trial DRKS00016773
title_short Minimally Invasive Versus open AbdominoThoracic Esophagectomy for esophageal carcinoma (MIVATE) — study protocol for a randomized controlled trial DRKS00016773
title_sort minimally invasive versus open abdominothoracic esophagectomy for esophageal carcinoma (mivate) — study protocol for a randomized controlled trial drks00016773
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7798277/
https://www.ncbi.nlm.nih.gov/pubmed/33430937
http://dx.doi.org/10.1186/s13063-020-04966-z
work_keys_str_mv AT nickelfelix minimallyinvasiveversusopenabdominothoracicesophagectomyforesophagealcarcinomamivatestudyprotocolforarandomizedcontrolledtrialdrks00016773
AT probstpascal minimallyinvasiveversusopenabdominothoracicesophagectomyforesophagealcarcinomamivatestudyprotocolforarandomizedcontrolledtrialdrks00016773
AT studierfischeralexander minimallyinvasiveversusopenabdominothoracicesophagectomyforesophagealcarcinomamivatestudyprotocolforarandomizedcontrolledtrialdrks00016773
AT nienhuserhenrik minimallyinvasiveversusopenabdominothoracicesophagectomyforesophagealcarcinomamivatestudyprotocolforarandomizedcontrolledtrialdrks00016773
AT paulyjana minimallyinvasiveversusopenabdominothoracicesophagectomyforesophagealcarcinomamivatestudyprotocolforarandomizedcontrolledtrialdrks00016773
AT kowalewskikarlfriedrich minimallyinvasiveversusopenabdominothoracicesophagectomyforesophagealcarcinomamivatestudyprotocolforarandomizedcontrolledtrialdrks00016773
AT weiterersebastian minimallyinvasiveversusopenabdominothoracicesophagectomyforesophagealcarcinomamivatestudyprotocolforarandomizedcontrolledtrialdrks00016773
AT knebelphilipp minimallyinvasiveversusopenabdominothoracicesophagectomyforesophagealcarcinomamivatestudyprotocolforarandomizedcontrolledtrialdrks00016773
AT dienermarkusk minimallyinvasiveversusopenabdominothoracicesophagectomyforesophagealcarcinomamivatestudyprotocolforarandomizedcontrolledtrialdrks00016773
AT weigandmarkusa minimallyinvasiveversusopenabdominothoracicesophagectomyforesophagealcarcinomamivatestudyprotocolforarandomizedcontrolledtrialdrks00016773
AT buchlermarkusw minimallyinvasiveversusopenabdominothoracicesophagectomyforesophagealcarcinomamivatestudyprotocolforarandomizedcontrolledtrialdrks00016773
AT schmidtthomas minimallyinvasiveversusopenabdominothoracicesophagectomyforesophagealcarcinomamivatestudyprotocolforarandomizedcontrolledtrialdrks00016773
AT mullerstichbeatp minimallyinvasiveversusopenabdominothoracicesophagectomyforesophagealcarcinomamivatestudyprotocolforarandomizedcontrolledtrialdrks00016773